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Abstract
Indoleamine 2,3-dioxygenase (IDO) can locally suppress T cell-mediated immune responses. It has been shown that
defective self-tolerance in early prediabetic female non-obese diabetic (NOD) mice can be attributed to the impaired
interferon-gamma (IFN-c)- induced IDO expression in dendritic cells of these animals. As IFN-c can induce IDO in both
dendritic cells and fibroblasts, we asked the question of whether there exists a similar defect in IFN-c-induced IDO
expression in NOD mice dermal fibroblasts. To this end, we examined the effect of IFN-c on expression of IDO and its
enzymatic activity in NOD dermal fibroblasts. The results showed that fibroblasts from either prediabetic (8 wks of age)
female or male, and diabetic female or male (12 and 24 wks of age respectively) NOD mice failed to express IDO in response
to IFN-c treatment. To find underlying mechanisms, we scrutinized the IFN- c signaling pathway and investigated
expression of other IFN-c-modulated factors including major histocompatibility complex class I (MHC-I) and type I collagen
(COL-I). The findings revealed a defect of signal transducer and activator of transcription 1 (STAT1) phosphorylation in NOD
cells relative to that of controls. Furthermore, we found an increase in MHC-I and suppression of COL-I expression in
fibroblasts from both NOD and control mice following IFN-c treatment; indicating that the impaired response to IFN-c in
NOD fibroblasts is specific to IDO gene. Finally, we showed that an IFN-c-independent IDO expression pathway i.e.
lipopolysaccharide (LPS)-mediated-c-Jun kinase is operative in NOD mice fibroblast. In conclusion, the findings of this study
for the first time indicate that IFN-c fails to induce IDO expression in NOD dermal fibroblasts; this may partially be due to
defective STAT1 phosphorylation in IFN-c-induced-IDO signaling pathway.
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Introduction
Indoleamine 2,3-dioxygenease (IDO), a rate limiting intracel-
lular enzyme, is involved in metabolism of tryptophan in the
biosynthesis pathway of nicotinamide adenine dinucleotide [1].
The importance of IDO in induction of self-tolerance and feto-
maternal tolerance during pregnancy in mice has been well
documented [1,2]. It is well established that IDO plays a
substantial role in modulation of T cell-mediated immune
responses. IDO-induced local tryptophan depletion and accu-
mulation of kynurenine (Kyn), a tryptophan metabolite, can
both contribute to the suppression of T cell-mediated immune
response [2–8].
Since the discovery of immunolegulatory characteristics of IDO,
this enzyme has been shown to have far-ranging roles in
mammalian pregnancy [2,5], autoimmune diseases [1,9], inflam-
mation and allergy [10], neoplasia [11,12] and most recently
inhibition of alloimmune responses in transplantation [13,14]. Our
research group has also shown that skin grafts survival is improved
in the presence of IDO-expressing-fibroblasts [15–20].
Grohmann and colleagues [9] have shown that tolerogenic
property of CD8
+ dendritic cells (DCs), mediated by IDO
expression, is impaired in early prediabetic non-obese diabetic
(NOD) mouse strain. They found that interferon-c (IFN-c), a
potent inducer of IDO expression, selectively fails to induce
tryptophan catabolism in CD8
+ DCs of early prediabetic female
NOD mice. They suggested that temporary blockade of a
renowned IFN-c signaling pathway, Janus kinase/signal transduc-
er and activator of transcription 1 (JAK/STAT1), caused by IFN-
c-induced-peroxynitrite generation, explains this phenomenon. As
IFN-c is a potent IDO inducer in many different cell types
including fibroblasts, here, we asked the question of whether there
exists a similar defect in IFN-c-induced IDO expression in dermal
fibroblasts from NOD mice and if so, whether this is limited to
pre-diabetic female mice. To address this, we investigated the IFN-
c-induced-IDO expression and tryptophan catabolism in dermal
fibroblasts of non-diabetic (C57BL/6 mice used as control group),
prediabetic (8 weeks of age) male and female, diabetic female (12
weeks of age) and male (24 weeks of age) NOD mice. The findings
showed that in contrast to C57BL/6 fibroblasts, NOD dermal
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37747fibroblasts from either prediabetic or diabetic animals, regardless
of their gender failed to express IDO in response to IFN-c
treatment. Further analysis revealed a defect in STAT1 phos-
phorylation as the potential underlying mechanism of this
phenomenon.
Results
IFN-c Fails to Induce Tryptophan Catabolism and IDO
Expression in Splenic DCs and Dermal Fibroblasts of NOD
Mice
To confirm the previous findings by Grohmann et al. [9],
splenic DCs were isolated from diabetic female NOD (.12 weeks
of age) and C57BL/6 mice and treated with 1000 U/ml of IFN-c
or left untreated for 24 hours. Cell pellets were subjected to RT-
PCR analysis for evaluation of IDO mRNA expression (Figure 1A).
Consistent with previous investigation, our result showed that in
contrary to C57BL/6 splenic DCs, IFN-c failed to induce IDO
mRNA expression in NOD splenic DCs. Next, we tend to
examine the IDO activity and tryptophan catabolism in dermal
fibroblasts from non-diabetic C57BL/6 (male, 12 weeks of age)
and diabetic NOD (female, 12 weeks of age; male, 24 weeks of age)
mice. Fibroblasts were treated with different doses of IFN-c for 48
hours. The conditioned media (CM) of the cells were then
subjected to Kyn measurement. The result shown in Figure 1B
indicates a dose dependent increase (11.3561.78, 15.5261.69 and
17.0561.81 mg/ml respectively) (P,0.01, n=6) in Kyn level in
CM from various concentrations of IFN-c-treated C57BL/6 cells
relative to that of untreated control (2.0861.09). However, there
was no increase in Kyn levels produced by IFN-c-treated female
NOD fibroblasts (1.7860.09, 1.6960.09 and 1.8160.08 mg/ml
respectively) or male NOD fibroblasts (1.8160.095, 1.7260.08,
1.7860.085 compared to that of non-treated ones (1.5760.05 and
1.8560.03 mg/ml for female and male NOD fibroblasts respec-
tively); suggesting that no active IDO proteins were present in
NOD fibroblasts. To further investigate at which level (i.e. mRNA
production or protein expression) this error occurred, fibroblast
RNA and cell lysates were subjected to RT-PCR and western blot
analysis, respectively. The results showed that, similar to the
enzymatic activity, IFN-c failed to induce IDO expression at the
protein (Figure 1C and 1D) and mRNA (Figure 1E and 1F) levels
in NOD dermal fibroblasts. Figures 1D and 1F represent the
quantitative analysis of the data shown in Figures 1C and 1E,
respectively. IDO protein and mRNA were remarkably expressed
in C57BL/6 cells in a dose-dependent manner in response to IFN-
c treatment (P,0.01, n=6). These data suggest that IFN-c-
mediated-tryptophan catabolism is impaired in dermal fibroblasts
of NOD mice.
To examine the effect of gender and diabetes status on IDO
induction by IFN-c, dermal fibroblasts isolated from prediabetic
male and female NOD mice (8 week of age) and control male
C57BL/6 mice (8 weeks of age) were treated with IFN-c for 48
hours. The level of Kyn, as an index for IDO activity, was
measured and our result showed that in contrary to C57BL/
6 cells, fibroblasts from neither male nor female prediabetic NOD
mice were able to catabolize tryptophan to Kyn (Kyn levels
17.0560.28 mg/ml for C57BL/6 cells versus 1.6860.22 and
1.7160.14 mg/ml for female and male prediabetic NOD fibro-
blasts respectively) (Figure 2A). Comparing fibroblasts from female
and male prediabetic NOD with control cells, we found that
regardless of gender, dermal fibroblasts from 8 weeks old
prediabetic NOD mice fail to express IDO following IFN-c
treatment at the protein level. However, C57BL/6 cells signifi-
cantly expressed active IDO (P,0.01, n=6) (Figure 2B). The
quantitative analysis of the blots was also consistent with this result
(Figure 2C).
IFN-c Can Induce MHC-I Expression in Dermal Fibroblasts
of NOD Mice
In order to get insights into the mechanism underlying impaired
responsiveness of NOD fibroblasts to IFN-c, we first asked
whether the expression of other IFN-c-mediated genes is also
defective in these cells. As a well-established molecule upregulated
by IFN-c [21,22], we evaluated the major histocompatibility
complex class I (MHC-I) mRNA expression using RT-PCR in
dermal fibroblasts of 12 weeks old C57BL/6 (male) and diabetic
NOD (female) mice following treatment with IFN-c. Activation of
JAK/STAT1 signaling pathway has been previously shown to be
involved in IFN-c-mediated MHC-I upregulation [22]. In
addition to this, there are compelling evidences suggesting the
role of nuclear factor-kappaB (NF-kB) pathway in the regulation of
MHC class I gene expression [23]. Therefore, any defect in MHC-
I expression through JAK/STAT1 pathway, can be compensated
through the activity of NF-kB pathway. As shown in Figure 3A,
IFN-c significantly increased MHC-I mRNA expression in both
C57BL/6 and NOD fibroblasts compared to that of untreated
ones (P,0.05, n=6). The quantitative analysis of these signals
revealed a significant difference in MHC-I level between IFN-c
treated NOD fibroblasts and that of untreated control (P,0.05,
n=6) (Figure 3B). This data shows that IFN-c can bind to its
receptor at the surface of NOD fibroblasts and stimulates the
expression of MHC-I. As such the defect seen in IFN-c-induced-
IDO expression in NOD fibroblasts is likely to be specific to the
signaling pathway of IDO expression.
IFN-c Reduces Collagen Expression in Dermal Fibroblasts
of NOD Mice
It is well documented that IFN-c reduces the expression of
collagen through activity of CCAAT/enhancer-binding protein b
(C/EBPb), a JAK/STAT1-independent mediator [24]. To further
investigate the responsiveness of other genes to IFN-c, fibroblasts
from 12 weeks old male C57BL/6 and diabetic female NOD
fibroblasts were treated with IFN-c or left untreated for 48 hours.
The result showed a significant difference in type I collagen (COL-
1) expression between untreated and treated NOD fibroblasts at
the protein level (P,0.05, n=6) (Figure 4A). Interestingly, the
quantitative analysis showed that the expression of COL-1 in
untreated NOD fibroblasts was significantly lower compared to
that of C57BL/6 fibroblasts (P,0.01, n=6) (Figure 4B). Consis-
tent with the protein expression, the result of RT-PCR showed
that IFN-c was capable of suppressing COL-1 mRNA expression
significantly (P,0.05, n=6) in both treated C57BL/6 and NOD
fibroblasts compared to untreated cells (Figure 4C). The quanti-
tative analysis of RT-PCR assay is shown in Figure 4D.
Taken together, these results show that IFN-c receptor and
other IFN-c mediated-protein expression pathways seem to be
functional. This further confirms that the defect is specific for IFN-
c-induced-IDO expression pathway in dermal fibroblasts of NOD
mice.
IDO Gene-transduced NOD Fibroblasts Express IDO
To gain in-depth perspective on the mechanism underlying
impaired IFN-c-induced tryptophan catabolism in NOD dermal
fibroblasts, we next asked whether the ribosomal protein
production machinery is intact in these cells. In other words, we
investigated whether the NOD fibroblasts are capable of
translating IDO mRNA to functional IDO protein. To achieve
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florescent protein (GFP) reporter genes (Ad-IDO) to transduce
C57BL/6 (12 weeks of age, male mice) and diabetic NOD (12
weeks of age, female mice) dermal fibroblasts as described
previously [18]. A mock vector was used as control for IDO
bearing vector. A separate batch of fibroblasts from both NOD
and C57BL/6 mice were also treated with 1000 U/ml of IFN-c.
Microscopic evaluation of transfected NOD fibroblasts after 72
hours, confirmed the viability of the cells and successful
transfection as indicated by GFP expression under UV light
(Figure 5A). To investigate the efficacy of IDO transfection in
fibroblasts, conditioned media (CM) of the cells treated with IFN-c
or transduced with Ad-IDO were collected for Kyn measurement.
The result showed a significant increase (P,0.001) in Kyn levels in
CM of Ad-IDO transduced NOD (12.1360.94 mg/ml) and
C57BL/6 (14.0960.10 mg/ml) fibroblasts compared to untreated
cells (2.0960.14 and 1.9460.22 for NOD and C57BL/6
fibroblasts respectively) suggesting the functionality of expressed
IDO in these cells. In contrary to NOD fibroblasts (Kyn level
1.7460.19 mg/ml), C57BL/6 fibroblasts were able to catabolize
tryptophan following IFN-c treatment markedly (Kyn level
16.9760.10 mg/ml) (P,0.001, n=6). (Figure 5B).
For assessing IDO expression at protein and mRNA level, the
Ad-IDO transduced cells were harvested and both protein and
mRNA expressions were evaluated by western blot analysis and
RT-PCR, respectively. The results confirmed a high level of IDO
Figure 1. Effect of IFN-c on IDO expression in splenic DCs and dermal fibroblasts of NOD mice. Tryptophan catabolism and IDO
expression at the protein and mRNA levels in cultured splenic CD11c
+ DCs and fibroblasts from non-diabetic male C57BL/6 mice (solid bars), diabetic
female NOD mice at 12 weeks of age (open bars), and diabetic male NOD mice (hatched bars) at 24 weeks of age following IFN-c treatment. Splenic
DCs were treated with 1000 U/ml of IFN-c or left untreated for 24 hours. Skin fibroblasts from both mouse strains were treated with increasing doses
of IFN-c (0, 250, 500, 1000 U/ml) for 48 hours. A: IDO mRNA expression in the treated splenic DCs, B: Kyn level in CM of the cells was measured as an
indicator of IDO activity. C: IDO expression at the protein level, E: IDO expression at mRNA level. D and F: the Mean6SEM ratio of densities of IDO to
b-actin at the protein and mRNA levels, respectively. b-actin and GAPDH were used as loading controls for western blotting and RT-PCR respectively.
*corresponds significant difference between C57BL/6 and NOD fibroblasts treated with same concentration of IFN-c (n=5, p,0.001). ND: not
detected.
doi:10.1371/journal.pone.0037747.g001
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C57BL/6 cells relative to vector treated cells (Figure 6A). The
quantitative analysis of the data is shown in Figure 6B (P,0.001,
n=6). Consistent with this, the result of RT-PCR analysis showed
that Ad-IDO transduced NOD and C57BL/6 fibroblasts mark-
edly expressed IDO mRNA (Figure 6C). The quantitative analysis
of this data is shown in Figure 6D (P,0.001, n=6). Collectively,
these results elucidate that the unresponsiveness of NOD
fibroblasts to IFN-c treatment in terms of IDO expression is not
due to a defect in translation of the IDO mRNA to IDO protein.
As such these findings suggest that this defect is likely to be at the
IFN-c-induced-IDO specific upstream signaling pathway.
Defective STAT1 Phosphorylation is Responsible for
Impaired IFN-c-induced Tryptophan Catabolism in NOD
Fibroblasts
It is well established that IFN-c activates phosphorylation of JAK
and subsequently STAT1. The phosphorylated STAT1 then
translocates to the nucleus and initiates transcription of responding
genes [25,26]. Knowing this, we monitored the STAT1 phosphor-
ylation in diabetic female NOD and male C57BL/6 dermal
fibroblasts following treatment with IFN-c at different time points
(0,15,30or60minutes).Theresultshowedthatfollowingtreatment,
IFN-cinducedSTAT1phosphorylationinC57BL/6fibroblastswith
a peak at 30 minutes. However, it failed to induce STAT1
phosphorylation in NOD fibroblasts (Figure 7A) (P,0.01, n=6).
The quantitative analysis of this data is shown in Figure 7B. The
expression of phosphorylated STAT1 was normalized to the
expressions of total STAT1 and b-actin. This finding indicates that
a defect in STAT1 phosphorylation should, at least in part, be
responsibleforIFN-cfailuretoinduceIDOexpressioninthesecells.
LPS Induces IDO Expression in NOD Dermal Fibroblasts
Using another IDO inducer, we next examined whether the
expression of IDO via an IFN-c-independent pathways is also
defective or not. To investigate this, C57BL/6 and NOD (12
weeks of age, male and female respectively) dermal fibroblasts
were treated with 1 mg/ml of lipopolysaccharide (LPS), derived
from Pseudomonas aeruginosa [27] for 24 hours. Using primary
murine microglia, it has been previously shown that LPS can
induce IDO expression via an IFN-c-independent mechanism
with a pick of enzymatic activity at 24 hours. This mechanism
depends upon activation of the c-Jun-N-terminal kinase (JNK)
pathway [28]. Our result showed that LPS was able to induce IDO
mRNA expression in both C57BL/6 and NOD dermal fibroblasts
(P,0.05, n=3) (Figure 8A). Figure 8B represents the quantitative
analysis of this data. Next, the control and test cells were treated
with 1 mg/ml of LPS in the presence or absence of SP600125
(10 mM), a JNK inhibitor, for 48 hours. The result of western blot
analysis showed that both C57BL/6 and diabetic NOD fibroblasts
markedly (P,0.05, n=3) expressed IDO following treatment with
LPS. This effect was partially reversed in the presence of the JNK
inhibitor (Figure 8C). The quantitative analysis of the data is
shown in Figure 8D. The result of Kyn assay was in parallel with
the protein assay and the data showed that both groups were able
to significantly catabolize tryptophan, while SP00125 partially
reversed this effect (Figure 8E). Again, this finding suggests that a
defect in STAT1 phosphorylation is likely to be responsible for
IFN-c failure to induce IDO expression in NOD fibroblasts.
Discussion
Knowing that IFN-c-induced IDO expression in many different
cell types including fibroblasts is important in controlling the
number and viability of CD4
+ and CD8
+ T cells [29], here we
asked the question of whether IFN-c induces the expression of
IDO in fibroblasts from an autoimmune diabetic mouse model.
We compared dermal fibroblasts from NOD and C57BL/6 mice
in terms of: 1) IFN-c-induced IDO expression and enzymatic
activity, 2) Other IFN-c-mediated pathways such as MHC-I
expression, 3) Modulation of COL-I expression, 4) IDO protein
Figure 2. Different effect of IFN-c on IDO expression in dermal
fibroblasts of C57BL/6 prediabetic NOD mice. Dermal fibroblasts
from prediabetic (8 weeks of age) male and female NOD mice failed to
respond to IFN-c induced IDO. Dermal fibroblasts isolated from C57BL/6
male mice of 8 weeks of age as control (solid bars), and aged matched
male (hatched bars) or female (open bars) prediabetic NOD mice were
treated with 1000 U/ml of IFN-c for 48 hours. A: Kyn levels in CM of
treated cells, B: IDO expression at the protein level, C: the Mean6SEM
ratio of densities of IDO to b-actin at protein control group treated with
IFN-c (n=3, p,0.01). b-actin expression showed equal loading of
proteins. ND: not detected.
doi:10.1371/journal.pone.0037747.g002
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transducer in IFN-c-mediated-IDO expression pathway and
finally, 6) Ability of NOD cells to express IDO in response to an
IFN-c-independent stimulus such as LPS.
Our results showed that IFN-c fails to induce IDO expression in
dermal fibroblasts of NOD mice. The NOD strain of mouse is a
renowned animal model of autoimmune diabetes. This strain
develops a spontaneous T cell-mediated destruction of pancreatic
beta cells with a higher incidence in females compared to males.
The onset of diabetes is about at 12 to 14 weeks of age in females
and shortly after in male NOD mice [30]. In this study, we
evaluated the effect of IFN-c in expression and enzymatic activity
of IDO in a selection of NOD mice; diabetic (female, 12 weeks of
age; male, 24 weeks of age) and prediabetic (8 weeks of age, female
or male) NOD mice were examined. The rationale for this
selection was the previous observation in tolerogeneic DCs,
suggesting that only DCs from early prediabetic female NOD
mice fail to express IDO following IFN-c treatment. The findings
revealed that differentially from DCs, dermal fibroblasts from
none of these groups expressed IDO and as a result no enzyme
activity was found as evaluated by measurement of Kyn level.
Considering the fact that type I diabetes is developed by massive
infiltration of T cells in pancreatic islets and expression of IDO
have a T cell suppressive effect [29], it would be important to
understand how IDO expression is involved in controlling the
pancreatic inflammation. Structurally, surrounds pancreatic islets,
there exists natural scaffold produced by fibroblasts [31].
Fibroblasts play a major role in improving the survival and
Figure 3. MHC-I mRNA expression in fibroblasts isolated from control and NOD mice. Cells were treated with 0 or 1000 U/ml of IFN-c for
48 hours. A: RT-PCR analysis of MHC-I mRNA expression. B: the Mean6SEM ratio of densities of MHC-I to GAPDH. Solid and open bars represent
C57BL/6 and NOD fibroblasts respectively. GAPDH was used as loading control. *denotes significant difference between C57BL/6 and NOD fibroblasts
treated with IFN-c in terms of MHC-I expression (n=3, p,0.05). **corresponds to significant difference between cells from the same strain treated
with 0 or 1000 U/ml of IFN-c (n=3, p,0.01).
doi:10.1371/journal.pone.0037747.g003
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fibroblasts to express IDO might also play a role in suppressing
autoreactive T cells invading pancreatic beta cells. It is likely that
IFN-c released from activated T cells induces IDO expression in
fibroblasts leading to a balance between tolerance and immune
response. Therefore, the findings of our study showing a defect in
tryptophan catabolism in diabetic fibroblasts along with those of
DCs can be partially involved in impaired tolerance towards
autoreactive T cells.
MHC-I molecule is an abundant protein found at the cell
surface of all nucleated cells. In fact these molecules play an
important role in initiation of T cell mediated events [32]. This
study showed that IFN-c is capable of inducing MHC-I in NOD
dermal fibroblasts. Moreover, COL-1 levels in cell lysates were
measured following IFN-c treatment. We found that IFN-c
decreased COL-1 expression in NOD dermal fibroblasts com-
pared to that of control fibroblasts. Our findings suggest that
impaired responsiveness of NOD fibroblasts to IFN-c is not due to
lack or dysfunction of cytokine receptor.
To further explore the mechanism underlying defective
tryptophan catabolism in NOD dermal fibroblasts, we asked
whether the protein machinery system of the cells is malfunction-
ing. Fibroblasts were transduced with IDO gene using adenoviral
vector. In contrary to our observation after IFN-c treatment,
NOD fibroblasts were able to express IDO post transduction. This
result proved that these cells are able to conduct transcription of
the IDO gene and translate it to functional protein; we concluded
that the defect in IFN-c-mediated-tryptophan catabolism in NOD
dermal fibroblasts is neither related to interaction of IFN-c with its
receptor nor gene transcription/translation mechanisms.
To get more insights into defective IDO expression in NOD
fibroblasts, STAT1 phosphorylation was evaluated following IFN-
c treatment. We provided evidence that protein STAT1 does not
get phosphorylated on tyrosine 701, impeding IFN-c-induced-
JAK/STAT1 pathway in NOD fibroblasts. This data was
consistent with previous observation of tolerogenic DCs in early
prediabetic NOD mice [9]. Thus, the blockade of JAK/STAT1
pathway in dermal fibroblasts from NOD mice is involved in a
defect in IFN-c induced-IDO expression.
Finally, we asked whether NOD dermal fibroblasts are able to
express IDO through an IFN-c-independent pathway. For this
reason, we treated both C57BL/6 and NOD dermal fibroblasts
with LPS. LPS has been shown to induce IDO expression in
primary rat glial cultures without an increase in detectible IFN-c
Figure 4. COL-I expression in dermal fibroblasts from control and NOD mice. COL-I expression in dermal fibroblasts from C57BL/6 (solid
bars) and NOD (open bars) mice was evaluated by western blot and RT-PCR analyses. Cells were exposed to 0 or 1000 U/ml of IFN-c for 48 hours
before analysis. A: COL-1 expression at the protein level. C: COL-1 expression at mRNA level. B and D represent the Mean6SEM ratio of COL-1 to b-
actin at protein and mRNA levels respectively. b-actin was used as loading control in both western blotting and RT-PCR assays. *demonstrates
significant difference between C57BL/6 and NOD fibroblasts treated with IFN-c in terms of COL-1 expression. **corresponds to significant difference
between cells from the same strain treated with 0 or 1000 U/ml of IFN-c (n=3, p,0.05).
doi:10.1371/journal.pone.0037747.g004
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factor for IDO induction through JAK/STAT1 pathway [25,35],
recent studies have revealed that IDO expression can be regulated
by other inflammatory stimuli, including tumor necrosis factor-a
and LPS [35]. LPS is shown to induce IDO expression through the
activity of mitogen activated-protein kinase JNK. These data
indicate that both IFN-c-dependent and -independent pathways
can mediate IDO expression. Our results showed that while IFN-c
fails to induce IDO expression in NOD dermal fibroblasts, these
cells are able to express significant levels of active IDO enzyme in
response to LPS treatment. Confirming the previous findings, our
results showed that the LPS-induced IDO expression most likely
occurs through JNK pathway. This finding suggests that
fibroblasts are unable to produce IDO in response to pro-
inflammatory cytokine i.e. IFN-c, which is released from immune
cells. However, these cells are competent to express IDO in the
defense against bacterial infections, where LPS could play an
important role in inducing this enzyme.
Inconclusion,thefindingsofthisstudyprovideevidencethatIFN-
cfailstoinduceIDOexpressionandtryptophancatabolismindermal
Figure 5. Tryptophan catabolism and microscopic evaluation of IDO expression in dermal fibroblasts following transduction with
Ad-IDO vector. Fibroblasts were treated with either blank medium or IFN-c (1000 U/ml), or transduced with Ad-IDO vector carrying GFP at an MOI
of 100. A: IDO and GFP expression in transfected fibroblasts. B: Increased levels of Kyn indicate that NOD (open bars) and C57BL/6 (solid bars)
fibroblasts express active IDO following IFN-c (48 h post-treatment) or Ad-IDO treatment (72 h-post transfection). *denotes significant difference
between related bars. (n=3, p,0.001). Data are reported as Mean6SEM. UT: untreated.
doi:10.1371/journal.pone.0037747.g005
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stages of diabetes. Moreover, our data suggest that this defect is
neither due to IFN-c receptor dysfunction nor protein expression
machineryofthesecells.WefoundthatimpairedSTAT1phosphor-
ylation might be partially responsible for this failure. Despite the
defect in JAK/STAT1 pathway, we showed that other IFN-c-
mediatedpathwayslikeIFN-c-inducedMHC-IexpressionorIFN-c-
mediated inhibition of COL-I production were still functional. As
stated before, both of these pathways can be activated independent
from JAK/STAT1. Therefore, the observed defect in this pathway
would not interfere with other aspects of IFN-c-mediated gene
expressionsandfunctions.AlthoughIFN-cfailstoinducetryptophan
catabolism in NOD dermal fibroblasts, activation of an IFN-c-
independent pathway i.e. LPS-mediated JNK pathway can resultin
expression of activeIDO enzyme.
Materials and Methods
Ethics Statement
This study has been approved by the University of British
Columbia Animal Care Committee. All animals used in this study
were maintained and undergone procedures in accordance with
the principles of laboratory animal care and the guidelines of the
University of British Columbia Animal Care Committee.
Cell Culture and Treatments
Dermal fibroblasts were explanted from skin punch biopsies
obtained from male C57BL/6 at 8 or 12 weeks of age, diabetic
female NOD mice at 12 weeks of age, diabetic male NOD mice at
24 weeks of age, and male/female prediabetic NOD mice at 8
weeks of age (The Jackson Laboratories, Bar Harbor, ME, USA).
As described previously [13], fibroblasts were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen Life
Technologies, Burlington, ON, Canada) supplemented by 10%
fetal bovine serum (FBS) (Hyclone Laboratories, Inc, Logan, UT,
USA), 100 U/ml penicillin, 100 mg/ml streptomycin and
0.25 mg/ml amphotericin B (Gibco, Invitrogen Incorporation,
NY, USA), incubated in a humidified incubator at 37uCi n5 %
CO2. Cells at passage three to five were used for this study.
Splenic DCs were isolated from diabetic female NOD mice
(.12 weeks of age) and fractioned based on CD11c expression
using pluriBeadH cell separation kit (pluriSelect GmbH, Leipzig,
Germany) according to manufacturer’s instructions. Isolated DCs
were cultured within RPMI-1640 (Hyclone Laboratories, Inc,
Logan, UT, USA) medium supplemented by 10% FBS, 100 U/ml
penicillin, 100 mg/ml streptomycin and 0.25 mg/ml amphotericin
B in 6-well flat bottom culture plates (Corning Incorporated,
Corning, NY, USA).
Fibroblasts were seeded on 6-well flat bottom cell culture plates
and treated with IFN-c (Sigma Chemicals, Oakville, ON, Canada)
at different concentrations (0, 250, 500 or 1000 U/ml of DMEM
plus 2% FBS) for either 24 hours (mRNA analysis) or 48 hours
(protein analysis). Subsequently, CM of the cells were collected for
Kyn assay and cell pellets were obtained for analyses of IDO,
MHC-I and COL-I expressions. CD11c
+ DCs were treated with
1000 U IFN-c per ml of RPMI-1640 medium plus 2% FBS or left
untreated for 24 hours. Then, pellets of DCs were collected for
evaluation of IDO mRNA expression.
To study IFN-c-induced-STAT1 phosphorylation, cells were
starved overnight and then treated with 1000 U/ml IFN-c or left
Figure 6. IDO protein and mRNA expression in Ad-IDO transfected cells. Dermal fibroblasts from C57BL/6 (solid bars) and NOD (open bars)
mice were transduced with Ad-IDO or mock vector. A: IDO expression was analyzed by western blotting, C: IDO expression was analyzed by RT-PCR.
B and D: the Mean6SEM ratio of IDO to b-actin at the protein and GAPDH at mRNA level (n=3). b-actin and GAPDH were used as a loading control
for protein and mRNA expression respectively. ND: not detected.
doi:10.1371/journal.pone.0037747.g006
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different time points (15, 30 and 60 minutes after treatment) and
cell pellets were collected for further analysis.
In an attempt to evaluate IDO expression via other IFN-c-
mediated pathways, LPS from Pseudomonas aeruginosa (Sigma, St.
Louis, MO) was used to induce IDO expression in C57BL/6 and
NOD dermal fibroblasts. Briefly, fibroblasts were seeded on 6-well
flatbottomcellcultureplatesandtreatedwith1 mg/mlofLPSorleft
untreated in DMEM plus 2% FBS. After 24 hours, fibroblasts were
harvested and subjected to mRNA isolation for IDO expression
analysis. To confirm whether the LPS-induced IDO expression is
mediatedviaJNKpathway,fibroblastsweretreatedwith1 mg/mlof
LPS in the presence or absence of SP600125 (10 mM) (Sigma, St.
Louis,MO),aJNKinhibitororleftuntreatedinDMEMplus2%FBS
for48hours.Subsequently,cellpelletswereanalyzedforIDOprotein
expression and CM were collected for Kyn assay.
Transduction of IDO Gene in Cells Using Adenoviral
Vector
Recombinant adenoviral vector carrying human IDO and GFP
(Ad-IDO) was constructed as described before [36], and used to
induce IDO expression in cells. Briefly, mouse dermal fibroblasts
were seeded on 6-well flat bottom cell culture plates and were
transfected with either Ad-IDO or a mock vector at 100
multiplicity of infection (MOI), or left untreated as control. Free
viral particles were washed out after 30 hours. The expression of
GFP was assessed using fluorescence microscopy (Nikone,
Melville, N, H-1010 AF) to confirm successful IDO transduction.
Kynurenine Assay
L-Kyn level was measured in CM of the treated cells as an
indicator of IDO activity, as described previously [13]. Brief-
ly, proteins were precipitated in CM samples using 30%
Figure 7. IFN-c-induced-STAT1 phosphorylation in C57BL/6 and NOD dermal fibroblasts. Following starvation for 18 hours, dermal
fibroblasts from NOD (open bars) and C57BL/6 (solid bars) mice were remained untreated or treated with 1000 U IFN-c per ml of DMEM plus 2% FBS
for 15, 30 or 60 minutes. Cell lysates were collected for western blot analysis. A: STAT 1 phosphorylation shown by western blotting. B: the
Mean6SEM ratio of phospho-STAT1 (P-STAT1), to the ratio of b-actin to total STAT1. Total STAT1 and b-actin expressions were used as loading
controls. *denotes significant difference between related bars (p,0.05, n=3). UT: untreated, ND: not detected.
doi:10.1371/journal.pone.0037747.g007
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500 ml of supernatant from each sample was incubated with one
volume of Ehrlich’s reagent (Sigma Chemicals, Oakville, ON,
Canada). The absorbance of the solution was measured at 490 nm
using spectrophotometry. Kyn levels were calculated using an
equation obtained from standard curve.
Western Blot Analyses of IDO and Collagen
IDO and COL-1 expressions were evaluated in mouse dermal
fibroblasts by the previously established method [19]. Briefly,
harvested cells were lysed in cell lysis buffer (containing 50 mM
Tris-HCL,pH 7.4;10 mMEDTA;5 mMEGTA;0.5%NonidetP-
40; 1% Triton X-100 and protease inhibitor cocktail (Sigma
Incorporation, Oakville, ON, Canada)). After resolution on SDS-
PAGE, proteins were transferred to PVDF membrane (Milipore
Corp.,Bedford,MA,USA).Membraneswereblottedwithpolyclonal
rabbit anti-human IDO antibody (1:1000; Washington Biotechnol-
ogyInc,Baltimore,MD, USA)todetect IDOormonoclonal mouse
anti-human COL-I antibodyfor collagen detection.
Western Blot Analysis of STAT1 Phosphorylation
To evaluate the status of STAT1 phosphorylation in response to
IFN-c, cell pellets were lyzed in cell lysis buffer containing
phosphatase inhibitor cocktail (Sigma Incorporation, Oakville,
ON, Canada). Samples were run on SDS-PAGE and transferred
to nitrocellulose membrane (Invitrogen, Carlsbad, CA, USA).
Immunoblotting was performed using rabbit anti-mouse STAT1
antibody or rabbit anti-mouse phospho-STAT1 antibody (1:1000;
Cell Signaling Technology, Inc. Danvers, MA, USA) according to
manufacturer’s protocol.
Reverse-Transcriptase Analyses of IDO, MHC-I
and Collagen
The total RNA in dermal fibroblasts was extracted using
RNeasy kit (Qiagen, Maryland, USA) based on manufacturer’s
instructions. Subsequently, cDNA was synthesized using Super-
Script RT-PCR system (Invitrogen, Carlsbad, CA, USA). The
primer’s used were as follows: IDO: sense 59-GGCACACGC-
TATGGAAAACT-39, antisense 59-CGGACATCTCCAT-
Figure 8. LPS-inducedIDOexpressioninC57BL/6andNODdermalfibroblasts.InpanelsAandB,C57BL/6(solidbars)andNOD(openbars)were
treatedwith0or1 mgofLPSfromPseudomonasaeruginosapermlofDMEMplus2%FBS,for24hours.A:RT-PCRanalysisofIDOmRNAexpression.B:the
Mean6SEM ratio of densities of IDO to b-actin. GAPDH was used as a loading control. In panels C, D and E, cells were treated with 1 mg/ml of LPS in the
presenceorabsenceofSP600125(10 mM),aJNKinhibitor,for48hours.C:westernblotanalysisofIDOexpression,D:theMean6SEMratioofdensitiesofIDO
tob-actin.E:TheKynlevelsindicatethatLPSinducedtheexpressionofactiveIDOenzymeinNODandC57BL/6fibroblasts,whichwasmediatedthroughJNK
pathway. *denotes significant difference between cells from the same strain treated with LPS with or without SP600125 (p,0.05, n=3). **represents
significantdifferencebetweenLPS-treatedandnon-treatedcellsfromthesamestrain(P,0.001,n=3).ND:notdetected.
doi:10.1371/journal.pone.0037747.g008
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2b2): 59-GCGAGGGTGGCTCTCACACG-39, antisense 59-
TCAGGGTGAGGGGCTCAGGC-39 product size 554 bp;
NOD mouse MHC-I (H-2kd): sense 59-GGGCGGCTCTCA-
CACGTTCC-39, antisense 59-
TCCCCTGCAGGCCTGGTCTC-39; mouse COL-I (Col 1a1):
sense 59-GACGCCATCAAGGTCTACTG-39, antisense 59-
ACGGGAATCCATCGGTCA-39, product size 154 bp; mouse
glyceraldehyde-3-phosphate dehydrogenase (GAPDH): sense 59-
TGGCACAGTCAAGGCTGAGA-3, antisense 59-
CTTCTGAGTGGCAGTGATGG-39 product size 384 bp;
mouse b-actin: sense 59–GTGGGCCGCCCTAGGCACCAA-
39, antisense 59–CTCTTTGATGTCACGCACGATTTC-39.
GAPDH and b-actin mRNA levels were used as internal controls.
RT-PCR cycles were optimized for each set of primers. The
numbers of cycles were as follows: 42 cycles for IDO, 38 cycles for
COL-1 and 38 cycles for MHC-I. Amplified RT-PCR products
were separated by electrophoresis on 1% agarose gel.
Statistical Analysis
Data are reported as Mean6SEM. The statistical analysis was
performed by one-way ANOVA followed by post hoc evaluation
using student’s t test for multiple comparisons to ensure the proper
distribution of variances. P-value of less than 0.05 was considered
statistically significant.
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